UNSPSC 51433937: Nicardipine hydrochloride

This classification denotes a calcium channel blockader, antihypertensive agent, and vasodilator agent with the molecular formula C26H29N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5BC5011K3, chemically known as 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-, 2-(benzylmethylamino)ethyl methyl ester, monohydrochloride but more generally known as nicardipine hydrochloride, which bears US NIH Compound Identifier 41114.

UNSPSC 51433937 Nicardipine hydrochloride, a Commodity code, covers the supply of specific pharmaceutical agents for emergency medical and institutional use. State and local governments procure this medication and related injectable pharmaceuticals primarily through city fire departments, county emergency services, and multistate cooperative purchasing alliances serving health departments and institutional healthcare facilities. The work being solicited involves providing pharmaceutical-grade vials and injections meeting expiration-date requirements, FDA compliance, cGMP certification, and Drug Supply Chain Security Act (DSCSA) compliance, with vendors responsible for delivery logistics, expiration management, and safety documentation per OSHA Hazard Communication Standards.

Geographic activity clusters in Florida and Minnesota, with multistate scope through cooperative purchasing vehicles. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem to supply Tampa Fire Rescue, with a response date of April 8, 2026 and an estimated contract value of $40,000; the award carries a one-year initial term with two optional one-year renewals plus three 30-day unilateral extensions, and includes a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products with a response date of March 26, 2026 and July 1, 2026 contract effective date; vendors must work through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) and pricing is weighted at 75 percent of evaluation criteria. The Texas Health and Human Services Commission issued an exploratory RFI in April 2026 regarding direct-to-manufacturer prescription programs, signaling potential future state-level procurement but without defined budget or binding timelines at the information-gathering stage.